Program
Aticaprant
Also written as “JNJ-67953964”, “14C-aticaprant” and “Aticaprant Supratherapeutic Dose”.
Its studies are mostly in Depressive Disorder, Major · Schizophrenia · Smoking · Alcoholism, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 121 open or running | phase 3since Jul 10, 2022 | Dec 15, 2015 | Jun 21, 2027phase 1 · NCT07615426 |
| Eli Lilly | 10 open or running | phase 1since Oct 20, 2010 | Oct 20, 2010 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 20, 2010First study: phase 1 study in AlcoholismNew to Eli LillyEli Lilly · NCT01232439 · 13 enrolled · United States
- Dec 15, 2015Johnson & Johnson's first study: phase 2 study in SmokingNew to Johnson & JohnsonJohnson & Johnson · NCT02641028 · 71 enrolled · United States
- Jun 6, 2018Phase 2 study in Depressive Disorder, MajorJohnson & Johnson · NCT03559192 · 181 enrolled · United States, Germany, Moldova, Republic of and more
- Dec 2, 2019Phase 1 study in HealthyJohnson & Johnson · NCT04185051 · 76 enrolled · Belgium
- Mar 9, 2021Phase 1 study in HealthyJohnson & Johnson · NCT04791332 · 30 enrolled · Japan
- Jan 17, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05197062 · 8 enrolled · Netherlands
- May 20, 2022Phase 1 study in HealthyJohnson & Johnson · NCT05387759 · 60 enrolled · Belgium
- Jul 10, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05455684 · 513 enrolled · United States, Argentina, Australia and more
- Aug 25, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05518149 · 871 enrolled · United States, Argentina, Australia and more
- Sep 20, 2022Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT05550532 · 444 enrolled · United States, Argentina, Brazil and more
- Jul 17, 2024Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT06514742 · 101 enrolled · United States, Belgium, Brazil and more
- Oct 9, 2024Phase 3 study in Depressive Disorder, MajorJohnson & Johnson · NCT06635135 · 47 enrolled · United States, Argentina, Belgium and more
- May 22, 2026Phase 1 study in SchizophreniaJohnson & Johnson · NCT07615426 · 64 planned · United States
Ahead
- Jun 21, 2027Primary completion: phase 1 study in SchizophreniaJohnson & Johnson · NCT07615426
TargetBeta
“Kappa opioid receptor antagonist”ChEMBL 37, by rule
Other programs on OPRK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| nalfurafinerule | toray-industries-inc | phase 3 | 9 |
| asimadolinerule | tioga-pharmaceuticals | phase 3 | 6 |
| icalcaprant | AbbVie | phase 2 | 6 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07615426Schizophrenia · United States | 1 | Recruiting | Johnson & Johnson | Jun 21, 2027 | 64 |
| NCT06635135Depressive Disorder, Major · United States, Argentina, Belgium and more | 3 | Terminated | Johnson & Johnson | Apr 9, 2025 | 47 |
| NCT06514742Depressive Disorder, Major · United States, Belgium, Brazil and more | 3 | Terminated | Johnson & Johnson | Apr 8, 2025 | 101 |
| NCT05550532Depressive Disorder, Major · United States, Argentina, Brazil and more | 3 | Completed | Johnson & Johnson | Nov 8, 2024 | 444 |
| NCT05518149Depressive Disorder, Major · United States, Argentina, Australia and more | 3 | Terminated | Johnson & Johnson | Apr 25, 2025 | 871 |
| NCT05455684Depressive Disorder, Major · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Sep 18, 2024 | 513 |
| NCT05387759Healthy · Belgium | 1 | Completed | Johnson & Johnson | Oct 4, 2022 | 60 |
| NCT05197062Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Mar 2, 2022 | 8 |
| NCT04791332Healthy · Japan | 1 | Completed | Johnson & Johnson | Jul 28, 2021 | 30 |
| NCT04185051Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 21, 2021 | 76 |
| NCT03559192Depressive Disorder, Major · United States, Germany, Moldova, Republic of and more | 2 | Completed | Johnson & Johnson | May 6, 2020 | 181 |
| NCT02641028Smoking · United States | 2 | Completed | Johnson & Johnson | Sep 13, 2016 | 71 |
| NCT01232439Alcoholism · United States | 1 | Completed | Eli Lilly | Apr 2011 | 13 |
How it is read
Names in the registry
- “Aticaprant”, 6 entries
- “JNJ-67953964”, 3 entries
- “14C-aticaprant”, 1 entry
- “Aticaprant Supratherapeutic Dose”, 1 entry
- “Aticaprant Therapeutic Dose”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 6 studies
- Schizophrenia, 1 study
- Smoking, 1 study
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.